Xencor (NASDAQ:XNCR) Stock Price Up 3.9% - Time to Buy?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s stock price was up 3.9% on Thursday . The stock traded as high as $13.62 and last traded at $13.65. Approximately 104,913 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 560,192 shares. The stock had previously closed at $13.14.

Wall Street Analysts Forecast Growth

XNCR has been the subject of several research reports. StockNews.com cut shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Finally, Piper Sandler raised Xencor from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $34.38.

Xencor Trading Down 2.3 %

The company has a 50 day simple moving average of $16.36 and a 200 day simple moving average of $20.32. The company has a market capitalization of $908.96 million, a PE ratio of -4.03 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Remove Ads

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Sterling Capital Management LLC increased its holdings in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Xencor in the fourth quarter valued at approximately $34,000. GAMMA Investing LLC increased its stake in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares during the last quarter. KBC Group NV raised its holdings in Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 1,213 shares in the last quarter. Finally, Quarry LP lifted its position in shares of Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $80,000 after buying an additional 2,108 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.